Clinical trial of danazol for benign breast disease.

Baker Hw, Snedecor Pa
In: The American surgeon · 1979 · vol. 45(11) , pp. 727–9 · PMID:391113 · W2407600746
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

A clinical trial found danazol provided relief of symptoms and nodularity in patients with fibrocystic breast disease, with mild side effects and symptom recurrence after discontinuation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A clinical trial of danazol was undertaken in 30 patients with severe fibrocystic disease of the breasts. Twenty-three of the patients continued the drug for five or six months to allow adequate evaluation. Partial or complete relief of breast pain, tenderness, and nodularity occurred in all patients studied. One previously unsuspected carcinoma of the breast was discovered after three months of therapy. Side effects from the drug were generally mild. Recurrence of symptoms and physical findings occurred in most patients after the drug was discontinued but have not been as severe as prior to therapy.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (6)

Source provenance

openalex
last seen: 2026-05-10T11:27:50.310468+00:00
License: CC0 · commercial use OK